Amendments to the Specification:

Please replace the paragraph on page 7, lines 5-12, with the following amended paragraph:

~~Figure 1-A and Figure 1B depict~~ Figure 1 depicts an N-linked oligosaccharide analysis of an anti-CD20 monoclonal antibody C2B8 by capillary electrophoresis with laser-induced fluorescence detection. ~~In Figure 1A~~ The upper graph of Figure 1 shows that C2B8 produced in 400L batch-fed culture produced at least three glycoforms of C2B8. ~~Figure 1B~~ The lower graph of Figure 1 depicts the same C2B8 preparation treated with β1-4 galactosyltransferase according the present invention. A single G2 glycoform preparation was obtained.

Please replace the paragraph on page 7, lines 14-19, with the following amended paragraph:

Figure 2 depicts an analysis of the galactosylation of an anti-VEGF monoclonal antibody by capillary electrophoresis. It can be seen that anti-VEGF produced in CHO cell culture produced at least three glycoforms. The same anti-VEGF treated with β-1-4 galactosyltransferase according to the present invention produced a single G2 glycoform.

Please replace the paragraph on page 7, lines 21-26, with the following amended paragraph:

Figure 3 depicts an analysis of the galactosylation of an anti-IgE monoclonal antibody, RhuMab-E25, by capillary electrophoresis. It can be seen that anti-IgE produced in CHO cell culture contained at least three glycoforms. The same anti-IgE CHO cell composition treated with β-1-4 galactosyltransferase according the present invention produced a single G2 glycoform.

Please replace the paragraph on page 7, lines 28-34, with the following amended paragraph:

Figure 4 depicts an analysis of the galactosylation of an anti-HER2 monoclonal antibody by capillary electrophoresis. It can be seen that anti-HER2 produced in CHO cell culture contained at least three glycoforms forming a heterogenous oligosaccharide population. The same anti-HER2 CHO composition treated with β-1-4 galactosyltransferase according to the present invention produced a single G2 glycoform.

Please replace the paragraph on page 8, lines 29-32, with the following amended paragraph:

Figure 9 depicts the correlation of bioactivity and galactose content in the G2 glycoform of rituximab. The G2 glycoform preparation was at least 1.5 times more active in this assay than that produced under typical cell culture conditions.

Please add the following after page 11, line 4 of the specification as filed:



G2



G1



G1



G-1



G0

Please replace the paragraph on page 50, lines 10-17, with the following amended paragraph:

~~Figure 1A and Figure 1B depict~~ Figure 1 depicts an oligosaccharide analysis of an anti-CD20 monoclonal antibody C2B8 by capillary electrophoresis with laser-induced fluorescence detection. ~~In Figure 1A~~ The upper graph of Figure 1 shows that C2B8 produced in 400L batch-fed culture produced at least three glycoforms of C2B8. ~~Figure 1B~~ The lower graph of Figure 1 depicts the same C2B8 preparation treated with β1-4 galactosyltransferase according the present invention. A single G2 glycoform preparation was obtained.

Amendments to the Drawings:

Attached are sheets of drawings for Figures 1-7B and 9 that have been annotated to show where changes have been made. Specifically, the titles have been removed from Figures 1-4, 7A, 7B and 9 and removed information has been inserted into Brief Description of the Drawings section. Further, the words "non-reduced" and "reduced" have been deleted from the bottom of Figures 5 and 6, respectively.

Also submitted herewith are formal drawings for Figures 1-9. Please replace Figures 1-9 as originally filed with the attached formal drawings.

Attachment: Annotated Sheets Showing Changes